News & Media

Newsroom

SK Life Science, Inc. Announces Campaign to Support Patient Recruitment in Ongoing Global Study for Adolescents Living with Primary Generalized Tonic-Clonic (PGTC) Seizures

07.31.2024

XCOPRI® (cenobamate tablets) CV Receives FDA Approval for Alternate Methods of Administration That Include Crushed Tablet in Liquid Suspension Taken Orally or Through a Nasogastric Tube

4.11.2024

SK Life Science Announces Data Presentations for XCOPRI® (cenobamate tablets) CV at the 2024 American Academy of Neurology Annual Meeting

4.9.2024

SK Life Science Appoints Dr. Sunita Misra, MD, PhD, as Vice President of Global Clinical Development and Acting Chief Medical Officer

4.8.2024

SK Life Science Celebrates Purple Day Highlighting Partnerships and Tools Designed to Empower People Living with Epilepsy in Their Journey to Achieve Zero Seizures

3.25.2024

Welcome to the news and information center for SK Life Science, Inc.

To learn more about SK Life Science, please download our corporate fact sheet

For more information about epilepsy, please download this infographic

For more information about Lennox-Gastaut syndrome, please download this fact sheet

X Community Guidelines

LinkedIn Community Guidelines

SK Life Science at a Glance

Headquarters Location: Paramus, NJ

R&D Begins: 1993

Parent Company: SK Life Science is a subsidiary of SK Biopharmaceuticals, CO., LTD, and both are a part of SK Group

Number of Employees: 200+ Employees

Disease Category Focus: CNS Disorders and Oncology

Pipeline: 8 compounds under clinical development

Top